About Lehe
乐于心,和与众,与己乐,与人和; 心宽念纯,百病无生。

If you find it difficult to understand the subsequent professional descriptions, you can quickly read through this text within two minutes.
Overview of the disease
Knowledge
Pancreatic cancer, known as the "king of cancers," is a tumor with extremely poor prognosis in clinical practice. The occurrence of pancreatic cancer is closely related to unhealthy lifestyles such as smoking, drinking, high-fat and high-protein diets, excessive coffee consumption, and genetic factors. Recent studies have shown that the incidence rate of pancreatic cancer in diabetic patients is significantly higher than that in the general population. Because there are usually no symptoms in the early stages, it is difficult to detect early, and often by the time it is diagnosed, metastasis has already occurred. As the disease progresses, tumor compression can cause symptoms such as jaundice and gastrointestinal bleeding.

Pancreatic cancer is highly malignant, and even after surgery, there is still a high risk of recurrence. Ms. Li and her family were very worried and sought the help of Professor Zhang Minghui's NKT treatment team at Tsinghua University School of Medicine. After carefully reviewing the case presentations of NKT cell therapy, they particularly hoped to try it to reduce the risk of tumor recurrence and delay the time of recurrence and metastasis.
2. The patient developed postoperative peritoneal and pelvic effusion, which is considered to be caused by surgery.
3. The patient's routine follow-up after chemotherapy revealed suspicious signals in the residual pancreas and right lobe of the liver. Combined with the elevated tumor marker levels, the possibility of disease progression in the patient has increased.
4. Currently, the patient has no clear signs of recurrence or metastasis. To prevent this, NKT cell therapy can effectively function in cases with low tumor burden. NKT cells can kill residual tumor cells, prevent the aggregation of free cancer cells, and effectively reduce the risk of metastasis and recurrence.
Imaging








Tumor markers
Tumor markers: CEA showed intermittent mild elevation from September 2019 to September 2021, and returned to normal range during follow-up from December 2021 to December 2022; CA125 and CA19-9 were within normal range from September 2019 to December 2022; NSE was within normal range in September 2021, slightly elevated in December 2021, returned to normal range during follow-up in June 2022, and exceeded normal range in December 2022, requiring close monitoring.

Conclusion and Comments
Ms. Li reported feeling more energetic than before. When she first finished her surgery, she needed assistance to walk and her quality of life score was only 78. Now, her appetite has improved, and her quality of life has been greatly enhanced. She reported fewer colds and fevers in spring and winter than before, and her overall quality of life is excellent, with a score of 90.5.

Reference:< H365>
【1】Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol. 2019; 30(5):781–787
Click on the image